Peptide · Fact sheet
Sermorelin
Also known as Geref · sermorelin acetate
Sermorelin is not currently available as an FDA-approved marketed drug product. The former Geref product was discontinued, and that history does not make current compounded versions FDA approved.
What is Sermorelin?
Sermorelin is a manufactured fragment of growth hormone-releasing hormone that can stimulate growth-hormone release from the pituitary gland.
A former branded product, Geref, had approved diagnostic and pediatric uses before being discontinued from marketing.
Benefits & claims
It is frequently promoted in anti-aging and body-composition contexts.
Those marketing claims need to be separated from the discontinued product's regulatory history and the limited evidence for today's promoted uses.
What the evidence supports
- Sermorelin can stimulate the growth-hormone pathway, which explains its historical diagnostic role.
- A biological effect does not by itself prove meaningful anti-aging, weight, or performance benefits.
Research areas
- Growth hormone secretion testing
- Growth hormone deficiency in historical contexts
- Growth hormone pathway effects
- Various growth-hormone-pathway outcomes outside a currently marketed FDA-approved product
Dosage & frequency
No established human regimenGeref is a discontinued FDA-approved sermorelin product. That historical approval does not establish a current compounded anti-aging schedule.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
Formulation differences
- Historical diagnostic or pediatric treatment use and present-day off-label preparations are different contexts.
Interactions & precautions
- Historical Geref evidence does not establish interactions for current off-label adult hormone combinations.
What is still unresolved
- A validated adult anti-aging regimen and long-term clinical benefits remain unestablished.
Side effects & risks
- Current compounded products do not undergo FDA premarket review for safety, effectiveness, or quality.
- Potential effects of stimulating the growth-hormone pathway can matter for glucose control, fluid retention, and other health conditions.
- Product purity, sterility, strength, and labeling are separate concerns for unapproved products.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Limited or unclear evidenceHuman physiology and the former product are documented, but high-quality evidence for many current wellness, anti-aging, or body-composition claims is limited or unclear.
Studies
Peer-reviewed review of sermorelin in diagnostic and therapeutic contexts.
Clinical literature on historical sermorelin use in pediatric growth-hormone deficiency.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
Explore 3 sourced accounts by reported effect.
Energy: reported experiences
Feeling tired but wired
A commenter using sermorelin with hexarelin described bodily heaviness, anxiety, an alert mind and difficulty sleeping, with stimulation again on a later exposure.
Reported use in this account
- Product
- Product labeled sermorelin/hexarelin combination
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Injection; specific route not stated
- Duration
- About two weeks
Other exposures described: Hexarelin
This combined exposure cannot identify sermorelin as the cause; contents and health context were unverified.
Read the original accountSleep: reported experiences
Feeling tired but wired
A commenter using sermorelin with hexarelin described bodily heaviness, anxiety, an alert mind and difficulty sleeping, with stimulation again on a later exposure.
Reported use in this account
- Product
- Product labeled sermorelin/hexarelin combination
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Injection; specific route not stated
- Duration
- About two weeks
Other exposures described: Hexarelin
This combined exposure cannot identify sermorelin as the cause; contents and health context were unverified.
Read the original accountBetter sleep during combined exposure
An adult described three months of use, alongside GHRP-2, newly started testosterone replacement and BPC-157.
Reported use in this account
- Product
- Product labeled sermorelin
- Amount
- 600 mcg, as reported
- Frequency
- Daily, at bedtime
- Route
- Not specified clearly
- Duration
- Three months
Other exposures described: GHRP-2; Testosterone replacement therapy; BPC-157
The two compounds cannot be separated, and the account lacks objective sleep measurements or verified product identity.
Read the original accountMood: reported experiences
Feeling tired but wired
A commenter using sermorelin with hexarelin described bodily heaviness, anxiety, an alert mind and difficulty sleeping, with stimulation again on a later exposure.
Reported use in this account
- Product
- Product labeled sermorelin/hexarelin combination
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Injection; specific route not stated
- Duration
- About two weeks
Other exposures described: Hexarelin
This combined exposure cannot identify sermorelin as the cause; contents and health context were unverified.
Read the original accountNo clear change: reported experiences
No noticeable improvement over three months
An author described little noticeable change during three months of sermorelin while also using BPC-157 and tirzepatide.
Reported use in this account
- Product
- Product labeled sermorelin
- Amount
- Not specified clearly
- Frequency
- Daily
- Route
- Injection; specific route not stated
- Duration
- Three months
Other exposures described: BPC-157; Tirzepatide
Concurrent exposures and limited outcome detail prevent isolating sermorelin or judging clinical effectiveness.
Read the original accountApproval status
The FDA-approved Geref product is discontinued from marketing. Current compounded sermorelin products are not FDA-approved drug products, and discontinuation history should be checked in Drugs@FDA.
Previously approved product discontinued
Geref, a sermorelin acetate product, was discontinued. A discontinued product is not the same as a currently marketed FDA-approved option for wellness or anti-aging use.
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
Open questions
- Long-term safety for commonly promoted off-label wellness goals
- Reliable benefits for anti-aging or body-composition claims
- Consistency and quality of products outside an approved drug application
Summary
Sermorelin's past approval does not confer approval on products sold today. Current claims should be evaluated against current product status and human evidence.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- fdaFederal Register: Geref discontinuation determination
FDA determination that the Geref discontinuation was not for safety or effectiveness reasons.
- fdaFDA review noting Geref discontinuation
FDA clinical pharmacology review referencing the discontinued Geref product.
- pubmedSermorelin in children with growth-hormone deficiency
Clinical literature on historical sermorelin use in pediatric growth-hormone deficiency.